18F-Fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts

  • Authors:
    • Satoshi Takeuchi
    • Songji Zhao
    • Yuji Kuge
    • Yan Zhao
    • Ken-Ichi Nishijima
    • Toshiyuki Hatano
    • Yasushi Shimizu
    • Ichiro Kinoshita
    • Nagara Tamaki
    • Hirotoshi Dosaka-Akita
  • View Affiliations

  • Published online on: June 7, 2011     https://doi.org/10.3892/or.2011.1338
  • Pages: 725-730
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We investigated whether 18F-fluorothymidine-positron-emission tomography/computed tomography (18F-FLT-PET/CT) is useful for the evaluation of the very early response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab therapy in human lung cancer xenografts. A human tumor xenograft model was established with a human non-small cell lung cancer cell line. The mice were randomly assigned to four groups: tumor growth follow-up, ex vivo study, PET/CT imaging and non-treated control. Mice were administered saline as control or cetuximab on day 1. An immunohistochemical study with Ki-67 was performed. Tumor volume treated with cetuximab was kept significantly smaller than control after day 8, although there was no difference on day 3. On day 3, 18F-FLT distribution was higher in the tumor than in other tissues, and was significantly decreased by treatment with cetuximab. On PET/CT imaging, 18F-FLT distribution in the tumor was clearly visualized, and the maximum standardized uptake value (SUV) was significantly decreased after treatment with cetuximab (p<0.01). Ki-67 expression was also significantly decreased on day 3 (p=0.01). These results suggest that 18F-FLT-PET/CT can be a useful predictor to determine the response to molecular targeted drugs such as cetuximab at an earlier time point than the change of tumor size.

Related Articles

Journal Cover

September 2011
Volume 26 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Takeuchi S, Zhao S, Kuge Y, Zhao Y, Nishijima K, Hatano T, Shimizu Y, Kinoshita I, Tamaki N, Dosaka-Akita H, Dosaka-Akita H, et al: 18F-Fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts. Oncol Rep 26: 725-730, 2011
APA
Takeuchi, S., Zhao, S., Kuge, Y., Zhao, Y., Nishijima, K., Hatano, T. ... Dosaka-Akita, H. (2011). 18F-Fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts. Oncology Reports, 26, 725-730. https://doi.org/10.3892/or.2011.1338
MLA
Takeuchi, S., Zhao, S., Kuge, Y., Zhao, Y., Nishijima, K., Hatano, T., Shimizu, Y., Kinoshita, I., Tamaki, N., Dosaka-Akita, H."18F-Fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts". Oncology Reports 26.3 (2011): 725-730.
Chicago
Takeuchi, S., Zhao, S., Kuge, Y., Zhao, Y., Nishijima, K., Hatano, T., Shimizu, Y., Kinoshita, I., Tamaki, N., Dosaka-Akita, H."18F-Fluorothymidine PET/CT as an early predictor of tumor response to treatment with cetuximab in human lung cancer xenografts". Oncology Reports 26, no. 3 (2011): 725-730. https://doi.org/10.3892/or.2011.1338